Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEASE-CF: Allogeneic MSC Infusion in Adults With Cystic Fibrosis
NCT02866721Phase 1Completed
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Aug 2016
- Primary completion
- Aug 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MSV alogénicas in cystic fibrosis (CF), sponsored by University Hospitals Cleveland Medical Center. Primary endpoints: Dose Limiting Toxicity at 24 hours, Serious and Non-Serious Adverse Events at 1 year and 2 more. Started Aug 2016; status: completed.
02
Drugs
MSV alogénicas
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02866721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866721.